WHO Calls For Experts To Advise On New Treatments For TB As Drug Resistance Rises
The World Health Organization (WHO) is looking for experts in the health field to provide advice on how the treatment of tuberculosis can be modified to align with the changes in how the disease is affecting populations around the world.
The call is aimed at forming a Technical Advisory Group on the dosing of TB medicines for adults and children, comprising experts on pharmacology of TB medicines, as well as pharmacometricians, researchers, clinicians, including pediatricians, and people with experience in the programmatic management of TB in various settings.
Tuberculosis (TB) remains one of the world’s deadliest infectious killers and is a major cause of ill health and suffering. Until the coronavirus disease (COVID-19) pandemic, TB was the top cause of death due to a single infectious agent. In 2021, an estimated 10.6 million people fell ill with TB, (including 1.15 million children) and 1.6 million people died of TB.
Globally, the success rate for people treated for TB in 2020 was 86%. However, without treatment, the death rate from TB disease is high (about 50%). The burden of drug-resistant forms of TB is estimated to have increased between 2020 and 2021, with an estimated 450 000 new cases of rifampicin-resistant TB (RR-TB) in 2021.
“Stopping TB infection from progressing to disease through the use of TB preventive treatment (TPT) is a critical and effective intervention to reduce TB incidence to the levels envisaged by WHO’s End TB Strategy,” the Organization has noted.
In Uganda, Multi-drug resistant tuberculosis has been a challenge and the Ministry of Health as revealed that a new strain that is resistant to all the drugs that were normally used to treat it has arisen as is a case of concern.
Uganda is still one of the 30 TB-burdened areas in the world, particularly in Kampala Metropolitan Area, Mukono and Wakiso, according to the Minister for Health Dr. Jane Ruth Aceng.
WHO’s team of experts will provide an independent evaluation and advice to WHO on scientific and technical aspects of dosing of anti-tuberculosis medicines for children and adults with all forms of TB and advise the agency on the new developments in the dosing and drug delivery approaches of medicines used in its care.
Deadline for application is 4th September 2023.
Apply here.

